# Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)

> **NCT04951323** · PHASE3 · UNKNOWN · sponsor: **University of Liege** · enrollment: 50 (estimated)

## Conditions studied

- Coronavirus Disease 2019 (Covid19)
- Hematopoietic Neoplasms

## Interventions

- **DRUG:** anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)

## Key facts

- **NCT ID:** NCT04951323
- **Lead sponsor:** University of Liege
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-22
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951323, "Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04951323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*